Transforming Growth Factor-β Signaling in Glomerular Diseases: Mechanisms of Fibrosis and Therapeutic Perspectives
Pathobiology · 30.09.2026 · 1-1
DOI: 10.1159/pat/aehag007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathobiology, online erschienen am 30.09.2026. Verfasst von Karen Martins Mendes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Research Center, Federal University of Triângulo Mineiro - UFTM, Uberaba, Brazil. Die Arbeit nennt 72 Literaturangaben.
Abstract (Originalsprache)
Background: Glomerular diseases are major drivers of CKD and end-stage renal failure worldwide. Transforming growth factor-β (TGF-β) is a central molecular regulator that integrates inflammatory, metabolic, and extracellular matrix remodeling pathways, thereby promoting renal fibrosis. Summary: This review synthesizes current evidence regarding TGF-β in glomerular diseases, emphasizing its context-dependent networks across distinct compartments of the renal microenvironment. Canonical SMAD signaling coordinates transcription of profibrotic genes, while noncanonical pathways (MAPK, PI3K/AKT, and Rho GTPases) amplify inflammatory and metabolic signaling. Rather than a uniform signaling pathway, TGF-β is shaped by disease-specific triggers, driving podocyte injury, mesangial activation, and progressive fibrotic remodeling. Despite strong experimental support, global inhibition of TGF-β has shown limited clinical success due to its pleiotropic roles in immune regulation and tissue homeostasis. Therapeutic strategies focused on selective modulation of distinct components, including SMAD3 inhibition, microRNA-based interventions, and extracellular vesicle-mediated delivery systems, show promise in attenuating profibrotic signaling while preserving physiological functions. In parallel, advances in biomarker discovery and transcriptomic profiling support biomarker-guided patient stratification and precision-based therapeutic approaches. Key Messages: TGF-β signaling is a major regulator of fibrogenesis in glomerular diseases but exerts context-dependent effects. Selective targeting of pathogenic signaling nodes, rather than global inhibition, combined with biomarker-guided stratification, represents a more effective therapeutic strategy. TGF-β remains a compelling therapeutic target in glomerular diseases, and integrating selective pathway modulation with biomarker approaches may enable successful interventions to limit fibrosis and slow CKD progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kidney Research Center, Federal University of Triângulo Mineiro - UFTM, Uberaba, Brazil.
- Division of General Pathology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
- Kidney Research Center, Federal University of Triângulo Mineiro - UFTM, Uberaba, Brazil, regia.fusco@uftm.edu.br.
- Division of General Pathology, Federal University of Triângulo Mineiro, Uberaba, Brazil, regia.fusco@uftm.edu.br.
Zitieren
APA
Mendes, K. M., Trevisan, R. O., Carvalho da Silva, A. L., Munhoz de Lion Siervo, G. E., Antônia Dos Reis, M., Peixoto Lira, R. C., & Machado, J. R. (2026). Transforming Growth Factor-β Signaling in Glomerular Diseases: Mechanisms of Fibrosis and Therapeutic Perspectives. Pathobiology, 1-1. https://doi.org/10.1159/pat/aehag007
Vancouver
Mendes KM, Trevisan RO, Carvalho da Silva AL, Munhoz de Lion Siervo GE, Antônia Dos Reis M, Peixoto Lira RC, et al. Transforming Growth Factor-β Signaling in Glomerular Diseases: Mechanisms of Fibrosis and Therapeutic Perspectives. Pathobiology. 2026:1-1. doi:10.1159/pat/aehag007
BibTeX
@article{Mendes2026,
author = {Mendes, Karen Martins and Trevisan, Rafael Obata and Carvalho da Silva, Ana Laura and Munhoz de Lion Siervo, Gláucia Eloisa and Antônia Dos Reis, Marlene and Peixoto Lira, Régia Caroline and Machado, Juliana Reis},
title = {Transforming Growth Factor-β Signaling in Glomerular Diseases: Mechanisms of Fibrosis and Therapeutic Perspectives},
journal = {Pathobiology},
year = {2026},
pages = {1--1},
doi = {10.1159/pat/aehag007}
}
EUVIMED